Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Go back to Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 217.36 +0.21 (0.10%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $217.15 | 52 Week High | $333.65 | |||
| Open | $221.00 | 52 Week Low | $223.02 | |||
| Day High | $222.25 | P/E | 27.83 | |||
| Day Low | $215.56 | EPS | $7.81 | |||
| Volume | 629,904 | |||||
